1
Orphan Designations
0 approved, 1 designated
0
FDA Approvals
1
Active Trials
200 recruiting
2
Rare Diseases
across 3 areas
0
News (30d)
Quiet
Avacta Life Sciences Ltd. is a company with 1 orphan drug designation across 2 rare diseases. Active clinical trials in 1 indication.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| sarcoma | - | Des.TrialAppr. |
| soft tissue sarcoma | N-[(2R)-1-[(2S)-2-[(3-hydroxy-2-methyl-6-{[(3S)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl]oxy}oxan-4-yl)carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]pyridine-4-carboxamide | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
14
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
14
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
0
affecting portfolio